

Appendix 3. Raw and crude data for testing, incidence, and prevalence calculations

Supplemental Table S4. Raw testing count data for individuals that received their first test in the observation window.

	Any Test*	Antibody	RNA	Viral Load	Genotype
<i>Individuals Tested, N (%)</i>					
Total, N	20,481	20,467	1,611	993	963
Single Testers, N (%)	-	13,596 (66.4%)	952 (59.1%)	611 (61.5%)	840 (87.2%)
Repeat Testers, N (%)	-	6,871 (33.6%)	659 (40.9%)	382 (38.5%)	123 (12.8%)
Positive Testers, N (%)	-	2,073 (10.1%)	1,030 (63.9%)	-	-
<i>Number of Tests</i>					
Total, N	39,291	33,714	2,917	1,569	1,091
Positive Tests, N (%)	-	3,943 (11.7%)	1,669 (57.2%)	-	-
<i>Number of Unique Testing Dates</i>					
Total, N		3,100	1,454	1,056	842
Unique Positive Testing Dates, N(%)	-	1,852 (59.7%)	1,102 (75.6%)	-	-

Note: Repeat tests were estimated from the presence of multiple tests of the same type at different sample collection dates for the same individual

*Corresponds to either an antibody, RNA, viral load or genotype test

Supplemental Table S5. Raw count data for point prevalence of ever tested and point prevalence of diagnosed cases calculations

Year*	Overall†			Reside within First Nations Communities			Reside outside First Nations Communities		
	Ever Tested	Existing Cases	Population Total	Ever Tested	Existing Cases	Population Total	Ever Tested	Existing Cases	Population Total
2006	9778	1439	156845	3179	166	55097	6596	1271	101694
2007	11470	1642	156850‡	3762	201	54876‡	7706	1439	101927‡
2008	12994	1851	157745	4218	243	54826	8774	1606	102869
2009	14570	2053	158532	4836	280	55379	9732	1772	103104
2010	16408	2258	158939	5454	321	55406	10952	1936	103482
2011	18570	2450	159083	6317	347	55967	12251	2102	103076
2012	21142	2655	158337	7606	429	55674	13535	2225	102630
2013	23351	2853	156313	8454	467	55034	14895	2384	101250
2014	25715	3145	153799	9311	567	53370	16399	2575	100402

*All values correspond to the number of individuals alive and in the province at December 31 of the calendar year

†Includes those with a missing or unknown community status during the respective year

‡ Presented is the population total for point prevalence of diagnosed cases, only for these values did the population total for the point prevalence of those ever tested differ by ≤ 5 due to removing individuals with first testing date more than a year after their death date as opposed to HCV diagnosis date.

Supplemental Table S6. Raw count and follow-up data for incidence rate of newly diagnosed cases

Year	Overall†		Reside within First Nations Communities		Reside outside First Nations Communities	
	New Cases	Follow-up Years	New Cases	Follow-up Years	New Cases	Follow-up Years
2006	210	159284.0	22	54823.6	181	100793.8
2007	247	158475.4	34	54526.2	206	100485.8
2008	252	158982.9	26	54490.5	223	101273.3
2009	253	158903.8	35	54887.1	214	101237.0
2010	266	158823.1	41	54923.4	222	101555.6
2011	270	158591.5	45	55488.7	222	101063.0
2012	283	158354.6	70	55485.2	211	101068.2
2013	279	156175.9	57	54981.4	219	99614.3
2014	363	153264.8	123	53244.0	236	98586.9

Note: Cases were diagnosed over the entire annual period. Cases were censored at the first of their date of HCV diagnosis, death, last contact date, or the end of the calendar year.

†Includes those with a missing or unknown community status during the respective year

Supplemental Table S7. Raw count and follow-up data for incidence rate of first test for infection

Year	Overall†		Reside within First Nations Communities		Reside outside First Nations Communities	
	Newly Tested	Follow-up Years	Newly Tested	Follow-up Years	Newly Tested	Follow-up Years
2006	1848	151587.7	587	52074.5	1237	95955.8
2007	1912	149231.6	625	51226.6	1261	94677.9
2008	1779	148294.7	559	50745.2	1198	94488.6
2009	1837	146889.6	625	50587.2	1191	93691.6
2010	2181	145357.9	778	50121.5	1382	93052.9
2011	2526	143325.8	889	49922.3	1613	91527.7
2012	2974	140813.7	1353	48874.0	1608	90305.2
2013	2630	136456.0	1012	47385.8	1598	87650.2
2014	2794	131548.3	1095	44912.4	1685	85365.9

Note: Tests were tabulated over the entire annual period. Individuals were censored at the first date of their HCV test, death, last contact date, or the end of the calendar year.

†Includes those with a missing or unknown community status during the respective year

Supplemental Table S8. Crude and indirect age-sex standardized measures for point prevalence and incidence measures.


<i>Crude (95% CI)</i>												
	Overall†				Reside within First Nations Communities				Reside outside First Nations Communities			
Year	First Test per 1000 PY	Ever tested per 100 people	Newly diagnosed cases per 1000 PY	Diagnosed cases per 100 people	First Test per 1000 PY	Ever tested per 100 people	Newly diagnosed cases per 1000 PY	Diagnosed cases per 100 people	First Test per 1000 PY	Ever tested per 100 people	Newly diagnosed cases per 1000 PY	Diagnosed cases per 100 people
2006	12.19 (11.64–12.76)	6.23 (6.11–6.36)	1.32 (1.15–1.51)	0.92 (0.87–0.97)	11.27 (10.38–12.22)	5.77 (5.57–5.97)	0.40 (0.25–0.61)	0.30 (0.26–0.35)	12.89 (12.18–13.63)	6.49 (6.33–6.64)	1.80 (1.54–2.08)	1.25 (1.18–1.32)
2007	12.81 (12.24–13.40)	7.31 (7.18–7.45)	1.56 (1.37–1.77)	1.05 (1.00–1.10)	12.20 (11.26–13.20)	6.86 (6.64–7.08)	0.62 (0.43–0.87)	0.37 (0.32–0.42)	13.32 (12.59–14.07)	7.56 (7.39–7.73)	2.05 (1.78–2.35)	1.41 (1.34–1.49)
2008	12.00 (11.45–12.57)	8.24 (8.10–8.38)	1.59 (1.40–1.79)	1.17 (1.12–1.23)	11.02 (10.12–11.97)	7.69 (7.46–7.93)	0.48 (0.31–0.70)	0.44 (0.39–0.50)	12.68 (11.97–13.42)	8.53 (8.35–8.71)	2.20 (1.92–2.51)	1.56 (1.49–1.64)
2009	12.51 (11.94–13.09)	9.19 (9.04–9.34)	1.59 (1.40–1.80)	1.30 (1.24–1.35)	12.35 (11.41–13.36)	8.73 (8.49–8.98)	0.64 (0.44–0.89)	0.51 (0.45–0.57)	12.71 (12.00–13.45)	9.44 (9.25–9.63)	2.11 (1.84–2.42)	1.72 (1.64–1.80)
2010	15.00 (14.38–15.65)	10.32 (10.17–10.48)	1.67 (1.48–1.89)	1.42 (1.36–1.48)	15.52 (14.45–16.65)	9.84 (9.58–10.11)	0.75 (0.54–1.01)	0.58 (0.52–0.65)	14.85 (14.08–15.66)	10.58 (10.39–10.78)	2.19 (1.91–2.49)	1.87 (1.79–1.96)
2011	17.62 (16.94–18.33)	11.67 (11.51–11.84)	1.70 (1.51–1.92)	1.54 (1.48–1.60)	17.81 (16.66–19.02)	11.29 (11.01–11.57)	0.81 (0.59–1.09)	0.62 (0.56–0.69)	17.62 (16.77–18.50)	11.89 (11.68–12.10)	2.20 (1.92–2.51)	2.04 (1.95–2.13)
2012	21.12 (20.37–21.89)	13.35 (13.17–13.53)	1.79 (1.59–2.01)	1.68 (1.61–1.74)	27.68 (26.23–29.20)	13.66 (13.36–13.97)	1.26 (0.98–1.59)	0.77 (0.70–0.85)	17.81 (16.95–18.70)	13.19 (12.97–13.41)	2.09 (1.82–2.39)	2.17 (2.08–2.26)
2013	19.27 (18.54–20.02)	14.94 (14.75–15.13)	1.79 (1.58–2.01)	1.83 (1.76–1.89)	21.36 (20.06–22.71)	15.36 (15.04–15.69)	1.04 (0.79–1.34)	0.85 (0.77–0.93)	18.23 (17.35–19.15)	14.71 (14.48–14.95)	2.20 (1.92–2.51)	2.35 (2.26–2.45)
2014	21.24 (20.46–22.04)	16.72 (16.52–16.93)	2.37 (2.13–2.63)	2.04 (1.97–2.12)	24.38 (22.96–25.87)	17.45 (17.09–17.80)	2.31 (1.92–2.76)	1.06 (0.98–1.15)	19.74 (18.81–20.70)	16.33 (16.08–16.59)	2.39 (2.10–2.72)	2.56 (2.47–2.67)

Appendix 3, as supplied by the authors. Appendix to: Mendlowitz A, Bremner KE, Walker JD, et al. Hepatitis C virus infection in First Nations populations in Ontario from 2006 to 2014: a population-based retrospective cohort analysis. *CMAJ Open* 2021. DOI:10.9778/cmajo.20200164. Copyright © 2021 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup.cmajca.


<i>Indirect Age-Sex Standardized (95% CI)</i>												
	Overall†				Reside within First Nations Communities				Reside outside First Nations Communities			
Year	First Test per 1000 PY	Ever tested per 100 people	Newly diagnosed cases per 1000 PY	Diagnosed cases per 100 people	First Test per 1000 PY	Ever tested per 100 people	Newly diagnosed cases per 1000 PY	Diagnosed cases per 100 people	First Test per 1000 PY	Ever tested per 100 people	Newly diagnosed cases per 1000 PY	Diagnosed cases per 100 people
2006	12.05 (11.51–12.62)	6.33 (6.20–6.45)	1.32 (1.14–1.51)	0.94 (0.89–0.99)	11.48 (10.57–12.45)	6.11 (5.90–6.32)	0.42 (0.26–0.63)	0.32 (0.28–0.38)	12.60 (11.91–13.32)	6.44 (6.29–6.60)	1.76 (1.51–2.04)	1.25 (1.18–1.32)
2007	12.72 (12.16–13.31)	7.41 (7.28–7.55)	1.56 (1.37–1.77)	1.07 (1.02–1.12)	12.48 (11.52–13.50)	7.25 (7.02–7.48)	0.65 (0.45–0.91)	0.39 (0.34–0.45)	13.08 (12.36–13.82)	7.50 (7.33–7.67)	2.02 (1.75–2.31)	1.41 (1.34–1.48)
2008	11.96 (11.41–12.52)	8.34 (8.19–8.48)	1.59 (1.40–1.80)	1.19 (1.14–1.25)	11.32 (10.40–12.30)	8.13 (7.89–8.38)	0.50 (0.33–0.73)	0.47 (0.42–0.54)	12.48 (11.79–13.21)	8.44 (8.26–8.62)	2.17 (1.90–2.48)	1.55 (1.47–1.63)
2009	12.50 (11.94–13.09)	9.28 (9.13–9.43)	1.60 (1.41–1.81)	1.31 (1.26–1.37)	12.72 (11.74–13.75)	9.18 (8.93–9.45)	0.67 (0.46–0.93)	0.54 (0.47–0.60)	12.56 (11.86–13.30)	9.33 (9.15–9.52)	2.09 (1.82–2.39)	1.70 (1.62–1.78)
2010	15.05 (14.42–15.69)	10.39 (10.23–10.55)	1.68 (1.49–1.90)	1.43 (1.37–1.49)	16.03 (14.92–17.19)	10.34 (10.06–10.61)	0.78 (0.56–1.06)	0.61 (0.55–0.68)	14.71 (13.95–15.51)	10.42 (10.22–10.61)	2.16 (1.89–2.46)	1.83 (1.75–1.92)
2011	17.72 (17.03–18.42)	11.69 (11.52–11.85)	1.71 (1.51–1.93)	1.54 (1.48–1.60)	18.43 (17.24–19.68)	11.78 (11.49–12.07)	0.85 (0.62–1.13)	0.65 (0.58–0.72)	17.49 (16.65–18.37)	11.64 (11.44–11.85)	2.17 (1.89–2.47)	1.99 (1.90–2.07)
2012	21.26 (20.51–22.04)	13.26 (13.08–13.44)	1.79 (1.59–2.01)	1.66 (1.59–1.72)	28.74 (27.23–30.31)	14.14 (13.82–14.46)	1.31 (1.02–1.66)	0.80 (0.72–0.88)	17.68 (16.83–18.57)	12.82 (12.60–13.04)	2.06 (1.79–2.35)	2.09 (2.00–2.18)
2013	19.38 (18.65–20.14)	14.66 (14.47–14.85)	1.78 (1.57–2.00)	1.78 (1.71–1.84)	22.22 (20.87–23.63)	15.76 (15.42–16.10)	1.08 (0.81–1.39)	0.87 (0.79–0.95)	18.04 (17.17–18.95)	14.10 (13.88–14.33)	2.15 (1.87–2.45)	2.23 (2.14–2.32)
2014	21.31 (20.53–22.11)	16.20 (16.01–16.40)	2.34 (2.10–2.59)	1.96 (1.89–2.03)	25.37 (23.89–26.92)	17.66 (17.30–18.02)	2.38 (1.98–2.84)	1.07 (0.98–1.16)	19.48 (18.56–20.43)	15.48 (15.24–15.72)	2.32 (2.03–2.64)	2.40 (2.31–2.49)

†Includes those with a missing or unknown community status during the respective year
Abbreviations: PY, Person-years.

Appendix 3, as supplied by the authors. Appendix to: Mendlowitz A, Bremner KE, Walker JD, et al. Hepatitis C virus infection in First Nations populations in Ontario from 2006 to 2014: a population-based retrospective cohort analysis. *CMAJ Open* 2021. DOI:10.9778/cmaj.20200164. Copyright © 2021 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup.cmajca.



Supplemental Figure S1. (A and C) Annual sex-specific age standardized incidence of first test for HCV infection among Status First Nations individuals. (B and D) Annual sex-specific age standardized point prevalence of individuals ever tested for HCV infection among Status First Nations individuals measured at December 31st each calendar year. Whiskers represent 95% confidence intervals. Abbreviations: PY, person-years.



Supplemental Figure S2. (A and C) Annual sex-specific age standardized incidence of diagnosed infection among Status First Nations individuals. (B and D) Annual sex-specific age standardized point prevalence of diagnosed infection among Status First Nations individuals measured at December 31st each calendar year. Whiskers represent 95% confidence intervals. Abbreviations: PY, person-years.